Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Show more

Location: 42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States | Website: https://quoinpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

5.229M

52 Wk Range

$5.01 - $54.95

Previous Close

$9.01

Open

$9.01

Volume

2,522

Day Range

$8.89 - $9.01

Enterprise Value

181.2M

Cash

11.55M

Avg Qtr Burn

-2.254M

Insider Ownership

7.08%

Institutional Own.

7.20%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.